-+ 0.00%
-+ 0.00%
-+ 0.00%

Abbott wins CE Mark for Amulet 360 left atrial appendage occluder in Europe

PUBT·08/27/2026 13:02:08
Listen to the news
Abbott wins CE Mark for Amulet 360 left atrial appendage occluder in Europe
  • Abbott won CE Mark for its next-generation Amulet 360 left atrial appendage occluder for non-valvular AFib patients at stroke risk.
  • The device is designed to seal the left atrial appendage, potentially reducing reliance on long-term blood thinners.
  • VERITAS trial data showed 99.8% implant success; 93.9% achieved complete closure at 45 days with zero leaks over 3 mm.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608270900PR_NEWS_USPR_____CG34693) on August 27, 2026, and is solely responsible for the information contained therein.